A Ruiz, S Puig, J Malvehy, C Lazaro, M Lynch, A.M. Gimenez-Arnau, Ll Puig, J Sanchez-Conejo, X Estivill, T Castel.
“CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia” J Med Genet 36; 490-494 (1999)
Ruiz A, Nadal M, Puig S, Estivill X. “Cloning of the human phospholipase A2 activating protein (hPLAP) gene on the chromosome 9p21 melanoma deleted region” Gene 239: 155-161 (1999)
S Puig, J Castro, PJ Ventura, C Ascaso, J Malvehy, X Estivill, A Vilalta, M Lecha, T Castel. “Large deletions of chromosome 9p in cutaneous malignant melanoma identify patients with a high risk of developing metastases” Melanoma Research; 10: 231-236 (2000)
Moral A, Lafuente MJ, Lafuente A, Castel T, Balesta AM, Lecha M; Trias M, The MMM Group. The Use Erytrocyte Glutathione as a predictive marker for malignant melanoma. Anticancer Research 20: 4757-4760 (2000)
E Serra, E Ars, A Ravella, A Sanchez, S Puig, T Rosenbaum, X Estivill, C Lazaro. Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations. Human Genet 108: 416-429 (2001)
Asumalahti K, Veal C, Laitinen T, Suomela S, Allen M, Elomaa O, Moser M, de Cid R, Ripatti S, Vorechovsky I, Marcusson JA, Nakagawa H, Lazaro C, Estivill X, Capon F, Novelli G, The psoriasis consortium, et al. Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. Hum Mol Genet 2002; 11: 589-597.
Vidal-Sicart S, Pons F, Puig S, Ortega M, Vilalta A, Martín F, Rull R, Palou J, Castel T. Identification of the sentinel lymph node in patients with malignant melanoma: what are the reasons for mistakes? Eur J Nucl Med Mol Imaging 2003; 30(3):362-6
Vilella R, Benitez D, Mila J, Vilalta A, Rull R, Cuellar F, Conill C, Vidal-Sicart S, Costa J, Yachi E, Palou J, Malvehy J, Puig S, Martí R, Mellado B, Castel T. Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine. Int J Cancer 2003 Sep 10; 106(4):626-31.
Argenziano G, Soyer HP, Chimenti S, Malvehy J, Puig S et al. Dermoscopy of pigmented skin lesions. Results of a Consensus Meeting via Internet. J Am Acad Dermatol (2003) 48: 679-93
Yakobson E, Eisenberg S, Isacson R, Halle D, Levy-Lahad E, Catane R, Safro M, Sobolev V, Huot T, Peters G, Ruiz A, Malvehy J, Puig S, Chompret A, Avril MF, Shafir R, Peretz H, Paillerets BB. Eur J A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families. Hum Genet. 2003 Apr;11(4):288
Zalaudek I, Argenziano G, Ferrara G, Soyer HP, Corona R, Sera F, Cerroni L, Carbone A, Chiominto A, Cicale L, De Rosa G, Ferrari A, Hoffmann-Wellenhof R, Malvehy J, Peris K, Pizzichetta MA, Puig S, Scaqlvenzi M, Staibano S and Ruocco V. Clinically equivocal melanocytic skin lesions with features of regression: a dermoscopic-pathologycal study. Br J Dermatol (2004) 150: 64-71
Conill C, González-Cao M, Jorcano S, Puig S, Malvehy J, Martí R and Castel T. Temozolomide as profilaxis of melanoma brain metastases. Mel Res 2004: 14; 73-4
R. Vilella, D. Benítez, J. Milà, M. Lozano, R. Vilana, J. Pomes, X. Tomas, J. Costa, A. Vilalta, J. Malvehy, S. Puig, B. Mellado, R. Martí and T. Castel. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Cancer immunology immunotherapy 2004; 53: 651-8
Vidal-Sicart S, Pons F, Fuertes S, Vilalta A, Rull R, Puig S, Palou J, Ortega M, Castel T. Is the identification of in transit sentinel lymph nodes in malignant melanoma patients really necessary? Eur J Nucl Med Mol Imaging 2004; 31: 945-9
